In men the condition can cause decreased libido and impotence. Given the efficacy and safety profile demonstrated in clinical trials, I believe Dostinex will become a valuable treatment choice. In a clinical trial involving approximately 450 patients, Dostinex was compared with bromocriptine in treating hyperprolactinemia. Clinical studies also showed the safety profile of Dostinex compares favorably to bromocriptine. Two percent of 221 patients taking Dostinex discontinued treatment due to side effects during the eight-week study, versus six percent of 231 patients taking bromocriptine.
Nausea is the most common side effect of both drugs.
Dostinex is contraindicated in patients with uncontrolled hypertension or known hypersensitivity to ergot derivatives. The company was formed through a merger of Pharmacia AB and The Upjohn Company and began operating in November 1995. The company has a corporate management center in London and major research and manufacturing centers in the United States, Sweden and Italy. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.